MON-521 GLP-1 Receptor Agonists and Risk for Dialysis, Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease

Related

• GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk

  Diabetes, Obesity & Metabolism · 4 Oct 2026

• SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes

  Clinical Journal of the American Society of Nephrology · 4 Oct 2026

• SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs

  Diabetes & Vascular Disease Research · 4 Oct 2026

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026